The biological relevance of the perforin and Fas ligand (FasL) cytolytic pathways of CD8 + T lymphocytes (CTL) for cancer immunotherapy is controversial. We investigated the importance of these pathways in a murine renal cell carcinoma expressing influenza viral hemagglutinin as a defined surrogate antigen (Renca-HA). Following Renca-HA injection, all FasL-dysfunctional FasL gld/gld mice (n = 54) died from Renca-HA tumors by day 62. By contrast, perforin À/À (51%; n = 45)
Introduction
CTLs form the basis of adoptive T-cell therapy of cancer. Despite various optimizations of adoptive T-cell therapy (1), the majority of patients still fail to show objective cancer regression even in melanoma (1) and renal cell carcinoma (2), the two cancers most responsive to immunotherapy to date. To further improve T-cell immunotherapy against cancer, we thus need to understand the molecular basis of tumor eradication by CTL in vivo.
Two direct mechanisms of CTL cytotoxicity have been defined in vitro (3) . One involves the perforin (Pfp)-dependent exocytosis of lytic granules (4, 5) , whereas the second mechanism uses various apoptosis-inducing death ligands of the tumor necrosis factor (TNF) superfamily (6) . Decreased rejection of induced sarcomas and papillomas (7, 8) or spontaneous lymphomas (9) in Pfp À/À mice suggested that Pfp may be important for CTL cytotoxicity in vivo. Nonetheless, the adoptive transfer of Pfp-deficient CTL to tumor-bearing mice showed substantial antitumor therapeutic efficacy (10) (11) (12) . From these studies, no definite conclusions, however, could be drawn concerning the molecular basis of tumor elimination following T-cell transfer, the importance of any alternative cytotoxic pathways in Pfp-replete mice, functional dominance or redundancy of direct cytotoxic pathways, and the role of the biological characteristics of the tumor cells in determining the nature of the CTL effector functions.
Studies using the influenza viral hemagglutinin (HA) expressed as a model tumor antigen (Ag) in a renal cell adenocarcinoma (Renca-HA), as well as a self-Ag in pancreatic islet h cells in insulin-HA transgenic mice, showed that host HA-reactive CTL could eliminate HA-expressing tumor cells in the absence of diabetes (13) . Taking advantage of this Renca-HA model and T-cell receptor (TCR)-transgenic Cln-4 (Tg) mice (14) to generate CTL reactive to MHC class I-restricted HA 518-526 epitope, we investigated the significance of the CTL effector mechanisms involving Pfp or Fas ligand (FasL) pathways for tumor rejection in vivo. The study shows that CTL using FasL are efficient at causing regression of established Renca-HA tumors, most likely because FasL-mediated lysis can still be triggered by the low immunogenic peptide density presented by Renca-HA cells.
Materials and Methods
Mice. All BALB/c mice (7-12 wk) (16) . Digital images of the specimens were captured using Spectrum image software (Aperio Technologies, Inc.).
Cytotoxicity. Target tumor cells, pulsed with medium or various concentration of HA peptide for 90 min at 37jC, radiolabeled with 111 Inlabeled oxyquinoline (Amersham Health, Medi-Physics, Inc.), and washed, were incubated for 18 h with CTL effectors. After overnight incubation, supernatants were harvested and counted on a 1480 wizard 3 automatic g-counter (Perkin-Elmer Life and Analytical Sciences). Percent cytotoxicity was calculated as described previously (11) .
Statistics. Comparisons of mean values between the groups were analyzed using GraphPad Instat software (GraphPad Prism). Statistical significance of the differences was analyzed by using unpaired Student's t test or by ANOVA. Comparisons of survival curves estimated by KaplanMeïer plots using GraphPad Prizm were performed by the log-rank (MantelCox) test. All statistical tests were two-sided; P values of <0.05 were considered statistically significant. Supplementary Fig. S1 ). Concerning longterm survival, all SCID mice (n = 43) died with large Renca-HA tumors with a median survival of 62 days. By contrast, 51% of WT mice (28 of 55) were tumor-free at day 360 (Fig. 1A) Renca-HA growth, resulting in long term survival, whereas SCID or FasL gld/gld mice rapidly succumbed to tumor. Similarly, following Renca-HA (0.5 Â 10 6 ) i.v. injection, WT, Pfp À/À , and Fas lpr/lpr mice formed significantly fewer lung metastases compared with SCID or FasL gld/gld mice (Fig. 1B) . The requirement of FasL for Renca-HA rejection was further confirmed when administration of a FasL-blocking mAb but not its isotype control in WT, Pfp À/À , and Fas lpr/lpr mice abrogated the rejection of Renca-HA lung metastases (Fig. 1B) . Thus, the expression of functional FasL in the host seemed crucial for resisting the development of Renca-HA solid tumors.
Results

Antitumor
Activation of CTL in tumor-bearing mice. To dissect the mechanisms underlying the preferential effector pathway usage in tumor rejection, we compared tumor metastases in the lungs following Renca-HA (3 Â 10 6 ) i.v. injection in HA-specific TCR Tg PfpÀ/À and Tg gld/gld backgrounds. Reduced pulmonary metastases were found in all Tg mice compared with WT mice (Fig. 2A) .
Moreover, Tg
PfpÀ/À mice exhibited significantly fewer metastases compared with Tg gld/gld mice, suggesting that HA-specific CTL expressing FasL were more efficient at causing Renca-HA rejection.
We then analyzed the activation of HA-specific CTL in tumorbearing mice. We injected Renca-HA cells s.c. (5 Â 10 6 ) in WT, Tg, Tg PfpÀ/À , and Tg gld/gld mice, and evaluated the number of cells in tumor-draining LN (DLN) and contralateral LN (CLN) on day 4. The numbers of cells in the DLN of Renca-HA-bearing mice were significantly increased compared with the CLN in all of these mice. As expected, no differences were seen in nontumor-bearing mice (Fig. 2B) .
The gated CD8 + cells in the DLN of tumor-bearing WT, Tg, Tg PfpÀ/À , and Tg gld/gld mice analyzed on day 7 after tumor injection showed an up-regulated expression of CD25 and CD44 as well as a capacity to produce high amounts of IFN-g (Fig. 2C) 
Tg
PfpÀ/À or Tg gld/gld mice regressed these established lung metastases without any overt toxicity. However, Tg gld/gld CTL were far less efficient at promoting tumor regression when lower numbers of CTL (0.01 Â 10 6 ) were transferred (Fig. 3A) . In addition, the therapeutic benefit following transfer of Tg or Tg PfpÀ/À CTL was abolished by administration of FasL-blocking antibody mAb (Fig. 3B) . Activated Tg CTL did express increased granzyme B, Pfp and FasL (Fig. 3D) .
Thus, Tg PfpÀ/À CTL that use FasL were 100-fold more efficient on a per cell basis at promoting rejection of the Renca-HA tumor in vivo than Tg gld/gld CTL, despite the fact that the Fig. S2 ), produced equivalent amounts of IFN-g (Fig. 3D) , and trafficked to the site of tumor pulmonary metastases with similar efficacy as shown by the CD8 immunohistochemistry of lung sections from tumor-bearing mice (Fig. 3C) . In addition, staining of lungs with H&E revealed punctate infiltration of lymphoid cells into distinct areas of lungs where tumor cells were present (data not shown). These results show that FasL cytolytic effector mechanism is critical in CTL-mediated regression of Renca-HA tumors. Supplementary Fig. S3 ). This was confirmed by immunohistochemistry of tumor sections from Fas lpr/lpr or FasL gld/gld mice (Fig. 4A) Fig. S3; Fig. 4C ). We also examined whether Fas engagement on Renca-HA cells triggered productive apoptotic signaling. Engagement of Fas on Renca-HA cells by FasL expressed on CTL triggered tumor cell apoptosis as it was blocked by a pan-caspase inhibitor zVAD-FMK ( Supplementary Fig. S4A ). mol/L HA peptide was increased to 90%. This lysis was blocked by Pfp inhibitor concanamycin A (Fig. 5B) , suggesting that Renca-HA cells were not intrinsically resistant to Pfp-mediated lysis. In addition, FasL-mediated lysis of Renca-HA targets, treated overnight with IFNg and TNFa, by Tg PfpÀ/À CTL was in the same range as untreated targets, suggesting that presence of IFNg secreted by CTL in the 18-h CTL assay (Fig. 3D ) was sufficient to sensitize targets to FasL (Fig. 5B) .
Lytic activity of Tg or Tg PfpÀ/À CTL was also evaluated against Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein-overexpressing Renca (Renca-FLIP) cells resistant to death receptor-mediated apoptosis (18) . Tg CTL lysed both control Renca-FLAG and Renca-FLIP cells loaded with 10 À6 mol/L HA peptide, consistent with a dominant role for Pfp-mediated lysis ( Supplementary Fig. S6 ). By contrast, Tg usage was lost (Fig. 5C) . Following FasL-blocking mAb treatment, lysis by Tg PfpÀ/À CTL was reduced in 4T1 targets from 52% to 4.6% and in A20 from 75.9% to 11%.
Interestingly, treatment of human renal cell adenocarcinoma lines ACHN, TK-10, and UO-31 with recombinant FasL triggered apoptosis. This tumor cell apoptosis could be amplified by pretreatment with IFN-g and TNF-a, and was blocked by inhibitor zVAD-FMK (Fig. 5D) . Thus, FasL pathway of T-cell cytotoxicity plays a major role in cytolysis of tumor cells exposed to inflammatory cytokines such as IFN-g and TNF-a, and becomes particularly dominant under conditions of low tumor peptide presentation.
Antigen presented by tumor targets influences the nature of CTL response and effector cell degranulation. Specific antibodies reactive to cell surface HA allowed us to sort the Renca-HA transfectants that expressed low, intermediate, and high surface levels of HA (Fig. 6A ), yet similar levels of MHC class I (data not shown). Renca-HA low tumor cell lysis by Tg CTL in 18-h CTL assay was mediated predominantly by FasL pathway as it was blocked by FasL-neutralizing mAb but not by Pfp inhibitor concanamycin A (Fig. 6B) . In contrast, Renca-HA high cell lysis by Tg CTL was blocked only partially by FasL-neutralizing Ab but more efficiently by concanamycin A. Lysis of unsorted Renca-HA cells and Renca-HA intermediate cells by Tg CTL showed a contribution from both effector pathways (Fig. 6C) .
To understand the reason for the insensitivity of Renca-HA low targets to Pfp-mediated lysis, we investigated effector cell degranulation by measuring CD107a, a lysosomal-associated membrane glycoprotein (19) . Interestingly, a significant up-regulation of CTL pretreated 2 h with medium or with concanamycin A (top ). Percent-specific lysis of Renca-HA cells pretreated with medium or with TNF-a and IFN-g (500 U/mL each, overnight) by Tg PfpÀ/À CTL in the presence of FasL-neutralizing mAb or its isotype control (bottom ). *, P < 0.001 (two-sided unpaired t test) with respect to medium or isotype control. C, percent-specific lysis of 4T1, C-26, and A-20 tumor cells pulsed with 10 À10 mol/L (lo) or 10 À6 mol/L (hi) HA peptide at effector/target ratio 25:1. *, P < 0.001 (two-sided unpaired t test) with respect to the respective lysis values by Tg or Tg PfpÀ/À CTL. D, percent decrease in cell number of medium-or human TNF-aÀ, and IFN-gÀpretreated (100 U/mL, overnight) human renal cancer lines ACHN, TK-10, and UO-31 incubated with pan-caspase inhibitor zVAD-FMK or control analogue zFA-FMK (20 Amol/L) 1 h before the treatment with FasL (100 ng/mL). *, P < 0.001 (two-sided unpaired t test) with respect to the control. Columns and points, means (n = 3) from a representative of six (A ), two (B and C ), and three (D) independent experiments; bars, SD.
CD107a expression was observed in HA-specific clonotypic TCR Vh8.1 + Tg CTL following incubation for 6 h with Renca-HA high targets compared with Renca-HA targets presenting lower or no HA (Fig. 6D) . Thus, Renca-HA high tumor cell targets triggered degranulation in activated Tg CTL. In contrast, Renca-HA low targets failed to trigger degranulation, explaining why they are poor targets for Pfp-mediated cytolysis.
Discussion
We addressed the contribution of the two direct mechanisms of CD8 + T-cell cytotoxicity in the control of s.c. tumor and pulmonary metastases. In the murine model of Renca-HA cancer, where limiting levels of HA peptide are presented by tumor cells, the FasL pathway plays a dominant role in the antitumor response. Our findings provide the first clear evidence of the nonredundant antitumor roles of the Pfp and FasL effector mechanisms in vivo. Interestingly, following the adoptive transfer of Tg CTL identical to those used in our current study, the Pfp pathway was found to be 30-fold more efficient than FasL in inducing HA-reactive autoimmune diabetes in mice with HA-expressing pancreatic h cells (15) . Our study suggests that Renca-HA tumors are probably much more sensitive to the cytotoxic effects of FasL than pancreatic h cells. Endogenous cytokines may up-regulate Fas expression on tumor cells in vivo (20, 21) and further sensitize them to FasL-mediated lysis. Thus, the changes in the tumor microenvironment produced by an influx of activated CTL, coupled to the intrinsic biological characteristics of the tumor cells, seem to be crucially important in determining whether this tumor progresses or regresses. Consequently, our study explains why Pfp can be dispensable for antitumor activities of adoptively transferred CTL (10) (11) (12) 22) , in certain mouse tumor models.
Previous in vitro studies have shown that self-peptides differing by one amino acid (23, 24) , chemically modified peptides (25) , or low concentrations of peptides (26) only act as partial agonists for cytotoxic T cells as they lead to a reduced TCR signaling. This weaker intracellular signaling triggers FasL-mediated cytotoxicity but not Pfp-mediated cytolysis (27) . Our study using TCRtransgenic CD8 + T cells is in agreement with these findings. More importantly, our adoptive CTL transfer studies suggest that low levels of tumor peptide determine the characteristics of the CTL effector response and the subsequent therapeutic outcome. We would speculate that many tumors will not trigger engagement of the Pfp-mediated cytotoxic pathway in vivo, even if the T cells have all the relevant lytic machinery available to them.
We found no role of FasL-mediated cytotoxicity in the ''bystander'' lysis of Ag-deficient Renca targets by Tg
PfpÀ/À CTL (data not shown), suggesting that the eradication of tumor by Pfp À/À CTL seemingly requires a direct tumor/effector contact.
Antitumor effects involving tumor stroma are unlikely, as evident from the efficient FasL-dependent rejection of Renca-HA tumor in Fas lpr/lpr mice where the stroma should be resistant to FasL. However, the role of stromal cells in tumor rejection may be dependent on the tumor site or type. Cytokines such as IFN-g or TNF have been reported to have effects on tumor stroma in promoting tumor rejection in some models (28, 29) . We found also no role for TRAIL in Renca-HA lysis by HA-reactive CTL, although Renca cells are sensitive to TRAIL (18, 30) .
The FasL-mediated tumor eradication may also serve as an immunoselective pressure to select Fas-deficient/low and/or Agnegative tumor cells. This immunoselection has been reported in the context of CD4 + T cell-mediated response against Renca-HA tumor (31) and in other tumor models (32) . We have also observed that the s.c. Renca-HA tumors growing out in WT mice become HA and/or Fas negative. 4 The ultimate success of the antitumor T-cell response may thus rely not only on the efficacies of Pfp and FasL pathways to control the continuum of high Ag to low antigenic targets but also on various other mechanisms including activation of innate immune cells that infiltrate the tumor. Recently, the antitumor CTL response was shown to activate local natural killer cells to eliminate Ag-loss tumor variants (33) . Tumor destruction in vivo, by mechanisms other than direct CTLmediated cytotoxicity, is worthy of further investigation.
This study suggests that biological characteristics of the tumors, including their FasL sensitivity and the quantity of antigen presented in association with MHC class I, will play a major role in determining the efficacy of immunotherapy. Interestingly, some human renal carcinoma lines are susceptible to the apoptotic effects of FasL in vitro. In addition, pharmacologic agents such as the proteasome inhibitor bortezomib can sensitize tumor cells to apoptosis (30, 34) . It is thus tempting to speculate that certain human renal carcinomas that are/can be made sensitive to FasLmediated apoptosis would be more responsive to adoptive T-cell therapy. Promotion of FasL-mediated T-cell cytotoxicity in combination with other therapeutic strategies that sensitize tumor cells to apoptosis may thus offer significant future potential for effective cancer immunotherapy.
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